Spanish LupusPRO: Cross-cultural validation study for lupus

Lupus

Volumn 22, Issue 5, 2013, Pages 431-436

  Jolly, M ^a   Toloza, S ^b   Block, J ^a   Mikolaitis, R ^a   Kosinski, M ^c   Wallace, D ^d   Durran Barragan, S ^e   Bertoli, A ^f   Blazevic, I ^g   Vila L ^h   Cooray, D ⁱ   Moldovan, I ^j   Katsaros, E ^j   Weisman, M ^d   Torralba, K M ^k   Alarcon G ^l  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Hospital San Juan Bautista ^*  (Argentina)

^c QualityMetric   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e Univesidad de Guadalahara   (Mexico)

^f Instituto Reumatológico Strusberg   (Argentina)

^g HOSPITAL RAMOS MEJÍA   (Argentina)

^h UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l University of Alabama at Birmingham   (United States)

more..

Author keywords

health outcomes; health related quality of life; patient reported outcomes; systemic lupus erythematosus

Indexed keywords

HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADAPTATION; ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CRITERION RELATED VALIDITY; CULTURAL FACTOR; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HISPANIC; HUMAN; INTERNAL CONSISTENCY; LANGUAGE; LUPUSPRO QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SHORT FORM 36; SLEDAI; SOUTH AND CENTRAL AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS; TEST RETEST RELIABILITY; UNITED STATES; VALIDATION STUDY;

ADOLESCENT; ADULT; CROSS-CULTURAL COMPARISON; FEMALE; HUMANS; LATIN AMERICA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; YOUNG ADULT;

EID: 84875953677     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313476359     Document Type: Article

References (26)

1. Alarcon GS, McGwin G, Brooks K, et al. Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: A comparison of physician and patient visual analog scale scores. Arthritis Rheum. 2002 ; 47: 408-413
2. Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?. Lupus. 2004 ; 13: 924-926
3. FDA Guidance on Patient Reported Outcomes. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2010) (accessed 10.08.2012).
4. Jolly M, Pickard AS, Block JA, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Seminars in Arthritis & Rheumatism. 2012 ;:
5. Jolly M, Block JA, Mikolaitis RA, et al. Spanish LupusPRO: Cross-cultural validation study for lupus. Arthritis Rheum. 2011 ; 63: S725 - S725
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
7. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol. 1993 ; 46: 1417-1432
8. Aday LA Designing and conducting health surveys. 2 nd ed. San Francisco, CA: Jossey-Bass, INC., A Wiley Company, 1996.
9. Ware JE Quality of life and pharmacoeconomics in clinical trials. Spiker B, ed. Philadelphia: Lippincott-Raven ; 1996: 337-345.
10. EuroQoL - a new facility for the measurement of health related quality of life. Health Policy. 1990 ; 16: 199-208
11. Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 1209-1216
12. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-2558.
13. Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011 ; 20: 453-462
14. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis & Rheumatism 1996; 39: 363-369.
15. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Quality of Life Research. 1993 ; 2: 441-449
16. Mplus User's Guide. Los Angeles: Muthén & Muthén, 1998.
17. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling. 1999 ; 6: 1-55
18. McElhone K, Abbott J, Teh SL. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006; 15: 633-643.
19. Furie R, Petri M, Zamani O, D et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis & Rheumatism 2011; 63: 3918-30.
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 ; 23: 137-145
21. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. [Review]. Expert Review of Pharmacoeconomics & Outcomes Research 2011; 11: 455-68.
22. Kuriya B, Gladman DD, Ibañez D, et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 2008 ; 59: 181-185
23. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005; 44: 1267-1276.
24. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis & Rheumatism 2007; 57: 972-979.
25. Doward LS, McKenna SP, Whalley D, et al. The development of the L-QoL: A quality of life instrument specific to systemic lupus erythematosus. Annals of Rheumatic Diseases 2008; 59: 84-88.
26. Jolly M, Cornejo J, Mikolaitis RA, et al. LupusPRO and responsiveness to changes in health status and disease activity over time. Arthritis Rheum. 2011 ; 63: S898 - S898